Publications by authors named "Elodie Regnier"
Article Synopsis
- A study examined low-dose interleukin-2 (IL-2) as a treatment for 13 different autoimmune diseases, focusing on its ability to activate regulatory T cells (Tregs) which are crucial in managing these conditions.
- 81 patients received IL-2 over a span of treatment, resulting in significant Treg expansion and activation, with clinical improvements noted in the majority of the diseases assessed, particularly in conditions like ankylosing spondylitis and systemic lupus erythematosus.
- The findings suggest that IL-2 is well-tolerated and effective at targeting Tregs, indicating its potential as a valuable addition to future therapeutic strategies for autoimmune diseases.
The association between psoriatic arthritis (PsA) and psoriasis is well known, but some have suggested that other musculoskeletal (MSK) conditions might also be more common in patients with skin psoriasis compared with the general population. The aim of our study was to describe the prevalence of a large panel of MSK conditions, in consecutive patients with psoriasis according to skin phenotype. This was a cross-sectional study.
View Article and Find Full Text PDFObjective: Regulatory T cells (Tregs) prevent autoimmunity and control inflammation. Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential.
View Article and Find Full Text PDFGram-positive Streptococcus pyogenes (group A Streptococcus or GAS) is a major skin pathogen and interacts with keratinocytes in cutaneous tissues. GAS can cause diverse suppurative and inflammatory infections, such as cellulitis, a common acute bacterial dermo-hypodermitis with a high morbidity. Bacterial isolation yields from the lesions are low despite the strong local inflammation observed, raising numerous questions about the pathogenesis of the infection.
View Article and Find Full Text PDF